Company / Cash & Equivalents
Vir Biotechnology, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$232.2M
FY2025
5-year range
$222.9M / $436.6M
FY2021-FY2025
Trend
+4.1%
vs FY2024
Sector context
#73 of 207
Health Care
What the data says
At $232M, Vir Biotechnology, Inc.'s cash & equivalents ranks #73 of 207 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $232M.
Based on SEC 10-K filings.
$232M in FY2025 with a 5-year CAGR of -11.9%.
Declined from $242M to $232M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- -11.9%
- 10-Year CAGR
- -
Sector benchmark
#73 of 207 in Health CareTop 35% of 207This company $232.2M Sector average $669.5M
▼
-65.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 4.1% year-over-year.
- Ranks #73 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $232.2M | +4.1% |
| FY2024 | $222.9M | -7.7% |
| FY2023 | $241.6M | -30.5% |
| FY2022 | $347.8M | -20.3% |
| FY2021 | $436.6M | +0.0% |
| FY2020 | $436.6M | +299.3% |
| FY2019 | $109.3M | +129.7% |
| FY2018 | $47.6M | -74.7% |
| FY2017 | $187.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026